Search | Clinical Trials Finder

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Atrovent Respimat (20 mcg), COMBIVENT MDI (36/206 mcg), Combivent Respimat (20 mcg/100 mcg), Placebo via corresponding inhaler for blinding purposes; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 1,480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 87
States / cities: Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 74 more

Conditions: Amblyopia
Interventions: Atropine, Eye Patch; Drug · Device
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: Up to 6 Years
Enrollment: 419 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Bradycardia, Arrhythmias
Interventions: Atropine; Drug
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 1 Day to 2 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Healthy
Interventions: Atropine, Propranolol, Normal Saline; Drug
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 21 Years to 40 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Epiphora
Interventions: Atropine sulfate ophthalmic solution 0.005%, Vehicle arm; Drug
Lead sponsor: Rehan Ahmed; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 2
States / cities: Houston, Texas • Mesquite, Texas

Conditions: Myopia
Interventions: 0.01% atropine, 0.05% atropine; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Amblyopia
Interventions: Eye patch, spectacles, atropine; Device · Drug
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 7 Years to 17 Years
Enrollment: 507 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 3
States / cities: Baltimore, Maryland • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania

Conditions: Sarcoma, Alveolar Soft Part
Interventions: Cediranib, Sunitinib, Prochlorperazine, Promethazine, Benzodiazepine, Filgrastim, Sargramostim, Lomotil, Loperamide, Vitamin B6, Aquaphor, Acetaminophen, Levothyroxine, Warfarin; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 16 Years to 120 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Rhinitis, Seasonal, Allergic
Interventions: PSE 120 mg, CM 8 mg, Atr 0.36 mg, PSE 120 mg, CM 8 mg, Atr 0.24 mg, PSE 120 mg, CM 8 mg, Atr 0.12 mg, PSE 120 mg, CM 8 mg, Atropine 0.24 mg; Drug
Lead sponsor: Magna Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years to 60 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 4
States / cities: Stockbridge, Georgia • Louisville, Kentucky • Charleston, South Carolina + 1 more

Conditions: Neuromuscular Blockade
Interventions: Sugammadex 2 mg/kg, Sugammadex 4 mg/kg, Neostigmine + Glycopyrrolate, Neostigmine + Atropine; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 2 Years to 16 Years
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 11
States / cities: Los Angeles, California • Palo Alto, California • San Diego, California + 8 more

Conditions: Papillomavirus Infections, Cervical Intraepithelial Neoplasia, Carcinoma In Situ, Vulvar Neoplasms, Vulvar Diseases
Interventions: E7 TCR cells, Aldesleukin, Fludarabine, Cyclophosphamide, EKG, Biopsy, Chest CT and MRI or PET, PFT, Granisetron, Ondansetron, Droperidol, Prochlorperazine, Diphenoxylate HCL, Atropine sulfate, Codeine sulfate, Loperamide, Indomethacin, Acetaminophen, Diphenhydramine HCL, Hydroxyzine HCL, Meperidine; Biological · Drug · Diagnostic Test + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 2
States / cities: Bethesda, Maryland • New Brunswick, New Jersey

Conditions: Myopia
Interventions: Atropine 0.01% Ophthalmic Solution, Atropine 0.02% Ophthalmic Solution, Atropine 0.05% Ophthalmic Solution; Drug
Lead sponsor: University of California, Berkeley; Other
Eligibility: 18 Years to 40 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Berkeley, California

Conditions: Myopia
Interventions: Atropine, MiSight contact lenses; Drug · Device
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 5 Years to 12 Years
Enrollment: 348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Alzheimer Disease, Mild Cognitive Impairment, Delirium, Dementia, Amnestic, Cognitive Disorders
Interventions: Donepezil; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 55 Years to 95 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Asthma in Children
Interventions: Ipratropium Bromide; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 2 Years to 17 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Buffalo, New York • Charlotte, North Carolina • Salt Lake City, Utah

Conditions: Achalasia
Interventions: Atropine challenge, Esophageal muscle biopsy; Drug · Procedure
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Recurrent Platinum Resistant Epithelial Ovarian Carcinoma, Recurrent Epithelial Endometrial Carcinoma, Recurrent Epithelial Cervical Carcinoma
Interventions: Sacituzumab Govitecan, EKG, Brain MRI, CT scans, Tumor biopsy, Loperamide, Octreotide, Diphenoxylate/Atropine, Antiemetics; Drug · Diagnostic Test · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Asthma
Interventions: Combivent CFC MDI, Albuterol HFA MDI, Respimat Combivent; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 41
States / cities: Birmingham, Alabama • Los Angeles, California • Palmdale, California + 36 more

Conditions: Vasoconstriction, Vasodilation
Interventions: Handgrip Exercise Training, Acetylcholine, Adenosine Triphosphate, Atropine, Phenylephrine, Sodium Nitroprusside; Other · Drug
Lead sponsor: Colorado State University; Other
Eligibility: 18 Years to 85 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Fort Collins, Colorado

Conditions: Amblyopia
Interventions: Atropine, Patching, Near activities; Drug · Device · Procedure
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 7 Years to 12 Years
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania

Conditions: Exercise-Induced Laryngeal Obstruction, Dyspnea During Activity
Interventions: Ipratropium Bromide, Normal Saline (Placebo); Drug
Lead sponsor: Cook Children's Health Care System; Other
Eligibility: 8 Years to 17 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Prosper, Texas

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: tiotropium, ipratropium bromide / albuterol; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 327 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 10
States / cities: Phoenix, Arizona • Lakewood, California • Sepulveda, California + 7 more

Conditions: Accomodation, Biofeedback Training, Myopia
Interventions: Auditory biofeedback traing; Behavioral
Lead sponsor: State University of New York College of Optometry; Other
Eligibility: 8 Years to 15 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Long Beach, New York

Conditions: Tachycardia, Postural Orthostatic Tachycardia Syndrome
Interventions: DAXOR, QSweat, Intrinsic Heart Rate; Radiation · Procedure · Drug
Lead sponsor: Satish R. Raj; Other
Eligibility: 18 Years to 80 Years
Enrollment: 260 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1996 – 2029
U.S. locations: 1
States / cities: Nashville, Tennessee

Search by objective public record fields.

Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD)

Occlusion Versus Pharmacologic Therapy for Moderate Amblyopia

Heart Rate Response to Atropine Doses Less Than 0.1mg IV to Anesthetized Infants

Analysis of Atropine and Propranolol Induced Changes

Low-Dose Atropine Eye Drops for Excessive Tearing (Epiphora)

The Response to Atropine Drops (RAD) Study

An Evaluation of Treatment of Amblyopia in Children 7 To <18 Years Old

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

StahistRx Phase 2, Five-arm, Parallel Group, Active vs Active, Double-blind Study

Efficacy, Safety, and Pharmacokinetics of Sugammadex for Reversal of Neuromuscular Blockade (NMB) in Pediatric Participants (MK-8616-089)

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

An Investigation of Topical Ophthalmic Low-Dose Atropine on Pupil Size and Accommodation

Myopia Control: a Comparison Study Between Atropine and MiSight

Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly

Treating Respiratory Emergencies in Children Study

Comprehensive Esophageal Diagnostics Study

Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

4 Week 2 Way Crossover Double Blind Treatment Phase With Combivent CFC Versus Albuterol Followed by a 4 Week Open Label Combivent Respimat When All Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma

Role of Acetylcholine in Blood Flow Regulation in Healthy Adults: Effects of Age and Exercise Training

Trial Comparing Patching Versus Atropine for Amblyopia in 7 to < 13 Year Olds

Effect of Ipratropium Bromide on EILO

Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.

Assessment of Accommodation Behavior in Children Under Myopia Control Treatment (Pilot Study)

Pathophysiology of Orthostatic Intolerance